India on Thursday launched Bharat Biotech’s nasal Covid vaccine, iNCOVACC on the occasion of Republic Day.
Union Health Minister Mansukh Mandaviya and Science and Technology Minister Jitendra Singh together launched Bharat Biotech’s nasal Covid vaccine, iNCOVACC.
The nasal vaccine BBV154 received the Drugs Controller General of India’s (DCGI) approval in November for restricted emergency use among adults as a heterologous booster dose, the company said.
According to a statement issued by Bharat Biotech earlier, ‘iNCOVACC’ is priced at Rs 800 for private markets and at Rs 325 for supplies to the government of India and state governments iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results, the Hyderabad-based vaccine maker had said.
Clinical trials were conducted to evaluate iNCOVACC as a primary dose schedule and as a heterologous booster dose for subjects who have previously received two doses of either Covishield or Covaxin.
Product development and clinical trials for iNCOVACC were funded in part by the Government of India, through the Department of Biotechnology’s, COVID Suraksha Program.
A global media for the latest news, entertainment, music fashion, and more.
